AU2016215515B2 - Combination therapies - Google Patents

Combination therapies Download PDF

Info

Publication number
AU2016215515B2
AU2016215515B2 AU2016215515A AU2016215515A AU2016215515B2 AU 2016215515 B2 AU2016215515 B2 AU 2016215515B2 AU 2016215515 A AU2016215515 A AU 2016215515A AU 2016215515 A AU2016215515 A AU 2016215515A AU 2016215515 B2 AU2016215515 B2 AU 2016215515B2
Authority
AU
Australia
Prior art keywords
cancer
compound
inhibitor
hydroxyphenyl
nintedanib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016215515A
Other languages
English (en)
Other versions
AU2016215515A1 (en
Inventor
Daniel P. Gold
Miguel QUINTELA-FANDINO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spanish National Cancer Research Centre
Lite Strategy Inc
Original Assignee
Spanish National Cancer Res Centre
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spanish National Cancer Res Centre, Mei Pharma Inc filed Critical Spanish National Cancer Res Centre
Publication of AU2016215515A1 publication Critical patent/AU2016215515A1/en
Application granted granted Critical
Publication of AU2016215515B2 publication Critical patent/AU2016215515B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016215515A 2015-02-02 2016-02-01 Combination therapies Active AU2016215515B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562111030P 2015-02-02 2015-02-02
US62/111,030 2015-02-02
PCT/US2016/016008 WO2016126618A1 (en) 2015-02-02 2016-02-01 Combination therapies

Publications (2)

Publication Number Publication Date
AU2016215515A1 AU2016215515A1 (en) 2017-08-17
AU2016215515B2 true AU2016215515B2 (en) 2020-04-30

Family

ID=56564570

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016215515A Active AU2016215515B2 (en) 2015-02-02 2016-02-01 Combination therapies

Country Status (13)

Country Link
US (2) US10980774B2 (cg-RX-API-DMAC7.html)
EP (1) EP3253208B1 (cg-RX-API-DMAC7.html)
JP (1) JP6824906B2 (cg-RX-API-DMAC7.html)
CN (2) CN116139125A (cg-RX-API-DMAC7.html)
AU (1) AU2016215515B2 (cg-RX-API-DMAC7.html)
CA (1) CA2974123C (cg-RX-API-DMAC7.html)
DK (1) DK3253208T3 (cg-RX-API-DMAC7.html)
ES (1) ES2877712T3 (cg-RX-API-DMAC7.html)
HU (1) HUE054998T2 (cg-RX-API-DMAC7.html)
MX (1) MX381863B (cg-RX-API-DMAC7.html)
PL (1) PL3253208T3 (cg-RX-API-DMAC7.html)
PT (1) PT3253208T (cg-RX-API-DMAC7.html)
WO (1) WO2016126618A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3253208B1 (en) 2015-02-02 2021-05-05 MEI Pharma, Inc. Combination therapies for use in the treatment of breast cancer
CN106860867A (zh) * 2017-02-23 2017-06-20 中山大学 己糖激酶2特异性抑制剂在急性中枢神经系统损伤疾病中的应用
EP3600322A1 (en) * 2017-03-28 2020-02-05 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of muscular dystrophy
WO2019178605A1 (en) * 2018-03-16 2019-09-19 The Board Of Trustees Of The Leland Stanford Junior University Analysis of response to therapeutics in cancer
CN110917199A (zh) * 2019-11-22 2020-03-27 上海市肺科医院 一种小分子化合物在制备肺癌化疗增敏药物中的应用
JP2023530253A (ja) * 2020-06-11 2023-07-14 エムイーアイ ファーマ，インク． 併用療法
AU2023221260A1 (en) * 2022-02-16 2024-09-12 ImmunoMet Therapeutics, Inc. Oxphos inhibitors for use in treating cancer
WO2024137472A2 (en) * 2022-12-19 2024-06-27 Mei Pharma, Inc. Combination therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012061409A1 (en) * 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
DE1518002C3 (de) 1965-01-02 1975-01-23 Merck Patent Gmbh, 6100 Darmstadt Isoflavane und Isoflavene und Verfahren zu Ihrer Herstellung sowie diese enthaltende Arzneimittel
DE1543749A1 (de) 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
GB1433013A (cg-RX-API-DMAC7.html) 1973-06-08 1976-04-22
US4218489A (en) 1977-06-08 1980-08-19 Z-L Limited Partnership Antioxidants, antioxidant compositions and methods of preparing and using same
US4264509A (en) 1977-06-08 1981-04-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4157984A (en) 1977-06-08 1979-06-12 Z-L Limited Antioxidants, antioxidant compositions and methods of preparing and using same
US4232122A (en) 1979-01-17 1980-11-04 Z-L Limited Partnership Antioxidants, antioxidant compositions and methods of preparing and using same
US4368264A (en) 1979-03-19 1983-01-11 Z-L Limited Partnership Fermentation methods of preparing ergostadientriols
US4234577A (en) 1979-03-19 1980-11-18 Z-L Limited Partnership Ergostadientriols, compositions containing same, and methods of preparing and using same
US4366248A (en) 1979-04-11 1982-12-28 Z-L Limited Partnership Fermentation method of preparing antioxidants
US4366082A (en) 1979-04-11 1982-12-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4390559A (en) 1979-04-11 1983-06-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4447622A (en) 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
US4644012A (en) 1983-12-21 1987-02-17 Takeda Chemical Industries, Ltd. Treatment for osteoporosis
GB8626344D0 (en) 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
MX13485A (es) 1987-10-19 1993-05-01 Pfizer Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos
US5059609A (en) 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
DE69023906T2 (de) 1990-08-09 1996-04-11 Council Scient Ind Res Benzopyrane und Verfahren zu deren Herstellung.
JPH07507811A (ja) 1992-10-21 1995-08-31 ファイザー・インク． 鏡像異性のシス−３−（４，６−ジヒドロキシクロマン−３−イル−メチル）安息香酸
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5451603A (en) 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
US5792776A (en) 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
WO1996021443A1 (en) 1995-01-13 1996-07-18 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment
BR9606754A (pt) 1995-01-13 1998-01-06 Novo Nordisk As Uso de compostos processo para tratamento e profilaxia de ginecomastia idiopática ou fisiológia e novo detalhe característico ou combinação de detalhes
HUP9702244A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
HUP9702246A3 (en) 1995-01-20 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of degenerative cerebral disorders
BR9606767A (pt) 1995-01-20 1997-12-30 Novo Nordisk As Uso de compostos e processo para tratamento vasodilatador e profilaxia de por exemplo isquemia cerebral angina pectoris ou sindrome de raynaud
TW448046B (en) 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
US5849461A (en) 1995-08-01 1998-12-15 Shin-Etsu Chemical Co., Ltd. Chemically amplified positive resist composition
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
HUP9902683A3 (en) 1996-01-11 2001-08-28 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5756539A (en) 1996-07-11 1998-05-26 Novo Nordis A/S 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
WO1998002156A1 (en) 1996-07-12 1998-01-22 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for lowering intraocular pressure
EP0954307A1 (en) 1996-07-12 1999-11-10 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
US5919817A (en) 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5958967A (en) 1996-10-28 1999-09-28 Novo Nordisk A/S Cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
DE69717843T2 (de) 1996-10-28 2003-09-25 Novo Nordisk A/S, Bagsvaerd Cis-3,4-chromanderivate zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
US5994390A (en) 1996-10-28 1999-11-30 Novo Nordisk Trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
WO1998018774A1 (en) 1996-10-28 1998-05-07 Novo Nordisk A/S Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
JP2001502704A (ja) 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患又は症候群の予防又は処置において有用な新規ｃｉｓ―３，４―クロマン誘導体の新規の（―）―鏡像異性体
JP2001502703A (ja) 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ （−）―３，４―トランス―ジアリールクロマンの調製方法
ES2188909T3 (es) 1996-10-28 2003-07-01 Novo Nordisk As Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os
WO1998018778A1 (en) 1996-10-28 1998-05-07 Novo Nordisk A/S Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US6316494B1 (en) 1996-10-28 2001-11-13 Novo Nordisk A/S cis3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US6043269A (en) 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ZA979644B (en) 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
IL129622A0 (en) 1996-10-28 2000-02-29 Novo Nordisk As Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU4699997A (en) 1996-10-28 1998-05-22 Novo Nordisk A/S Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5985306A (en) 1996-10-28 1999-11-16 Novo Nordisk A/S (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes
JP3251946B2 (ja) 1996-12-13 2002-01-28 中外製薬株式会社 新規なベンゾピラン誘導体
ZA98682B (en) 1997-01-29 1998-07-29 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more psychiatric disorders
ZA98681B (en) 1997-01-29 1998-07-29 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibition senescense-associated motor impairment
WO1998033499A1 (en) 1997-01-29 1998-08-06 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for increasing libido in post-menopausal women
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
AUPP112497A0 (en) 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
AU3456499A (en) 1998-03-30 1999-10-18 University Of Mississippi, The Isoflavones for treating giardiasis and malaria
AU3407799A (en) 1998-04-28 1999-11-16 Novo Nordisk A/S Enzymatic resolvation for obtaining a (-)-3,4-trans-diarylchroman
FR2778404B1 (fr) 1998-05-06 2000-06-30 Hoechst Marion Roussel Inc Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
KR20000001793A (ko) 1998-06-13 2000-01-15 이경하 신규한 벤조피란 또는 티오벤조피란 유도체
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
AUPP868599A0 (en) 1999-02-15 1999-03-11 Novogen Research Pty Ltd Production of isoflavone derivatives
FR2789685B1 (fr) 1999-02-15 2001-05-04 Univ Lille Sciences Tech Procede de fabrication de polymeres solubles et insolubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) et polymeres solubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s)
AUPQ008299A0 (en) 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites
WO2001007031A1 (en) 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
WO2001026651A2 (en) 1999-10-14 2001-04-19 Endorecherche, Inc. Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
EP1241165A4 (en) 1999-12-13 2003-03-19 Chugai Pharmaceutical Co Ltd OPTICALLY ACTIVE CHROMANE AND THIOCHROMANE DERIVATIVES
US6479467B1 (en) 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
PL357163A1 (en) 2000-01-28 2004-07-26 Endorecherche, Inc. Selective estrogen receptor modulators in combination with estrogens
AU2001255709A1 (en) 2000-05-11 2001-11-20 Eastman Chemical Company Acylated cyclodextrin guest inclusion complexes
FI20001593A7 (fi) 2000-07-03 2002-01-04 Orion Yhtymo Oyj Comt-entsyymiõ inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia
CN1250505C (zh) 2000-08-31 2006-04-12 科学工业研究院 制备1－丙基－2，4，5－三甲氧基苯的改进方法
WO2002055562A2 (en) 2001-01-11 2002-07-18 Eastman Chem Co Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
ES2236485T3 (es) 2001-01-24 2005-07-16 Chiesi Farmaceutici S.P.A. Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos.
JP4313041B2 (ja) 2001-02-14 2009-08-12 ナームローゼ・フエンノートチヤツプ・オルガノン ２−アルキル化−シクロデキストリン誘導体：薬物性神経筋遮断に対する拮抗薬
EE200400061A (et) 2001-08-11 2004-04-15 Bristol-Myers Squibb Pharma Company Trifenüületüleeni derivaadid kui selektiivsed östrogeeniretseptori modulaatorid ja neid sisaldavad ravimkoostised
AU2002332878A1 (en) 2001-09-06 2003-03-24 Synorx, Inc. Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
EP1465619A1 (en) 2002-01-14 2004-10-13 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
CN1646119A (zh) 2002-04-09 2005-07-27 诺沃根研究有限公司 涉及异黄－3－烯和异黄烷结构的治疗方法和组合物
AU2002951833A0 (en) 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
MXPA05003591A (es) 2002-10-09 2005-09-30 Insert Therapeutics Inc Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
EP1685140A4 (en) 2003-11-18 2009-02-25 Novogen Res Pty Ltd PRODRUGS BASED ON ISOFLAVONOIDS, COMPOSITIONS THEREOF AND THERAPEUTIC PROCESSES INVOLVING THEM
CN101123958A (zh) 2003-11-19 2008-02-13 诺沃根研究股份有限公司 联合放射疗法与化学疗法的组合物和方法
DE102004002787A1 (de) 2004-01-19 2005-08-11 Merck Patent Gmbh Flavonoid-Komplexe
CA2581316C (en) 2004-09-21 2013-09-10 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
EP1809618B1 (en) 2004-09-21 2013-07-17 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
JP4913056B2 (ja) 2004-09-21 2012-04-11 マーシャル エドワーズ，インコーポレーテッド 置換クロマン誘導体、医薬品、および治療における使用
JP4976649B2 (ja) 2004-09-21 2012-07-18 マーシャル エドワーズ，インク． 化合物
AU2007314141A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
US20100173983A1 (en) 2007-03-16 2010-07-08 David Brown Method for inducing autophagy
JP2012500809A (ja) 2008-08-29 2012-01-12 ノボゲン リサーチ ピーティーワイ リミテッド 免疫調節活性
KR20110101135A (ko) 2008-10-22 2011-09-15 노보겐 리서치 피티와이 리미티드 예정 세포 사멸을 유도하는 방법
CA2641541A1 (en) 2008-10-22 2010-04-22 Novogen Research Pty Ltd. Methods for inducing programmed cell death
US20120251630A1 (en) * 2011-03-29 2012-10-04 Marshall Edwards, Inc. Remission therapy of cancer with isoflavonoids
BR112015006363A2 (pt) 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
MX368063B (es) 2014-02-07 2019-09-18 Novogen ltd Compuestos de benzopirano funcionalizados y uso de los mismos.
EP3253208B1 (en) * 2015-02-02 2021-05-05 MEI Pharma, Inc. Combination therapies for use in the treatment of breast cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012061409A1 (en) * 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer

Also Published As

Publication number Publication date
US12414934B2 (en) 2025-09-16
WO2016126618A1 (en) 2016-08-11
EP3253208A1 (en) 2017-12-13
HUE054998T2 (hu) 2021-10-28
EP3253208B1 (en) 2021-05-05
US20210267936A1 (en) 2021-09-02
CN116139125A (zh) 2023-05-23
PT3253208T (pt) 2021-06-17
MX381863B (es) 2025-03-13
PL3253208T3 (pl) 2021-11-08
EP3253208A4 (en) 2018-08-15
JP6824906B2 (ja) 2021-02-03
MX2017010002A (es) 2018-02-09
HK1243598A1 (zh) 2018-07-20
US20180015067A1 (en) 2018-01-18
JP2018503697A (ja) 2018-02-08
AU2016215515A1 (en) 2017-08-17
ES2877712T3 (es) 2021-11-17
DK3253208T3 (da) 2021-06-07
CN107427003B (zh) 2023-01-31
CA2974123C (en) 2023-08-01
CA2974123A1 (en) 2016-08-11
US10980774B2 (en) 2021-04-20
CN107427003A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
AU2016215515B2 (en) Combination therapies
US12329739B2 (en) Isoflavonoid compounds and methods for the treatment of cancer
HK1243598B (en) Combination therapies
WO2024137472A2 (en) Combination therapies
HK1189452B (en) Isoflavonoid compounds and methods for the treatment of cancer
HK1189452A (en) Isoflavonoid compounds and methods for the treatment of cancer
HK1189176B (en) Isoflavonoid compositions and methods for the treatment of cancer
HK1189176A (en) Isoflavonoid compositions and methods for the treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)